(Reuters) - Merck & Co has put on fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval, in an attempt to close the gap with competitors in two lucrative segments, the Wall Street Journal reported.
via Reuters: Health News Read More Here..
No comments:
Post a Comment